PMID- 27044833
OWN - NLM
STAT- MEDLINE
DCOM- 20161226
LR  - 20161230
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 79
DP  - 2016 Apr
TI  - Lupeol acetate ameliorates collagen-induced arthritis and osteoclastogenesis of 
      mice through improvement of microenvironment.
PG  - 231-40
LID - S0753-3322(15)30336-X [pii]
LID - 10.1016/j.biopha.2016.02.010 [doi]
AB  - Lupeol has been shown with anti-inflammation and antitumor capability, however, 
      the poor bioavailability limiting its applications in living subjects. Lupeol 
      acetate (LA), a derivative of lupeol, shows similar biological activities as 
      lupeol but with better bioavailability. Here RAW 264.7 cells and bone 
      marrow-derived macrophages (BMDMs) stimulated by lipopolysaccharide (LPS) were 
      treated with 0-80muM of LA, and assayed for TNF-alpha, IL-1beta, COX-2, MCP-1 using 
      Western blotting. Moreover, osteoclatogenesis was examined with reverse 
      transcription PCR (RT-PCR) and tartrate-resistant acid phosphatase (TRAP) 
      staining. For in vivo study, collagen-induced arthritis (CIA)-bearing DBA/1J mice 
      were randomly separated into three groups: vehicle, LA-treated (50mg/kg) and 
      curcumin-treated (100mg/kg). Therapeutic efficacies were assayed by the clinical 
      score, expression levels of serum cytokines including TNF-alpha and IL-1beta, 
      (18)F-fluorodeoxyglucose ((18)F-FDG) microPET/CT and histopathology. The results 
      showed that LA could inhibit the activation, migration, and formation of 
      osteoclastogenesis of macrophages in a dose-dependent manner. In RA-bearing mice, 
      the expressions of inflammation-related cytokines were suppressed, and clinical 
      symptoms and bone erosion were ameliorated by LA. The accumulation of (18)F-FDG 
      in the joints of RA-bearing mice was also significantly decreased by LA. The 
      results indicate that LA significantly improves the symptoms of RA by 
      down-regulating expressions of inflammatory cytokines and osteoclastogenesis.
CI  - Copyright (c) 2016 Elsevier Masson SAS. All rights reserved.
FAU - Wang, Wei-Hsun
AU  - Wang WH
AD  - Dept of Orthopedic Surgery, Changhua Christian Hospital, Changhua, Taiwan.
FAU - Chuang, Hui-Yen
AU  - Chuang HY
AD  - Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming 
      University, Taipei, Taiwan.
FAU - Chen, Chien-Hui
AU  - Chen CH
AD  - Department of Radiation Oncology, Chang-Gung Memorial Hospital, Taoyen, Taiwan.
FAU - Chen, Wun-Ke
AU  - Chen WK
AD  - Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming 
      University, Taipei, Taiwan; Department of Radiation Oncology, Hsinchu Branch, 
      Mackay Memorial Hospital, Hsinchu, Taiwan.
FAU - Hwang, Jeng-Jong
AU  - Hwang JJ
AD  - Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming 
      University, Taipei, Taiwan; Biophotonics & Molecular Imaging Research Center 
      (BMIRC), National Yang-Ming University, Taipei, Taiwan. Electronic address: 
      jjhwang@ym.edu.tw.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160311
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Pentacyclic Triterpenes)
RN  - 0 (RANK Ligand)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - O268W13H3O (lupeol)
SB  - IM
MH  - Animals
MH  - Arthritis, Experimental/*drug therapy/*pathology
MH  - Bone Marrow Cells
MH  - Cell Differentiation/drug effects
MH  - Cell Movement/drug effects
MH  - *Cellular Microenvironment/drug effects
MH  - Chemokine CCL2/metabolism
MH  - Cyclooxygenase 2/metabolism
MH  - Disease Models, Animal
MH  - Interleukin-1beta/metabolism
MH  - Lipopolysaccharides
MH  - Macrophages/metabolism
MH  - Mice
MH  - Osteoclasts/drug effects/*pathology
MH  - *Osteogenesis/drug effects
MH  - Pentacyclic Triterpenes/pharmacology/*therapeutic use
MH  - RANK Ligand/pharmacology
MH  - RAW 264.7 Cells
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Collagen-induced arthritis
OT  - Lupeol acetate
OT  - Macrophage
OT  - Osteoclastogenesis
OT  - RANKL
EDAT- 2016/04/06 06:00
MHDA- 2016/12/27 06:00
CRDT- 2016/04/06 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2016/02/23 00:00 [revised]
PHST- 2016/02/23 00:00 [accepted]
PHST- 2016/04/06 06:00 [entrez]
PHST- 2016/04/06 06:00 [pubmed]
PHST- 2016/12/27 06:00 [medline]
AID - S0753-3322(15)30336-X [pii]
AID - 10.1016/j.biopha.2016.02.010 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2016 Apr;79:231-40. doi: 10.1016/j.biopha.2016.02.010. Epub 
      2016 Mar 11.